167 related articles for article (PubMed ID: 24696231)
21. First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.
Pfister D; Oechsle K; Schmidt S; Busch J; Bokemeyer C; Heidenreich A; Heinzelbecker J; Ruf C; Winter C; Zengerling F; Kliesch S; Albers P; Oing C
World J Urol; 2022 Dec; 40(12):2853-2861. PubMed ID: 35226138
[TBL] [Abstract][Full Text] [Related]
22. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
23. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
24. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
25. [Results of the German studies (MAHO) for treatment of testicular germ cell tumors in children--an update].
Schmidt P; Haas RJ; Göbel U; Calaminus G
Klin Padiatr; 2002; 214(4):167-72. PubMed ID: 12165897
[TBL] [Abstract][Full Text] [Related]
26. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Klaproth H; Kubin T; Sayer HG; Hentrich M; Welslau M; Mayer F; Kuczyk M; Spott C; Kanz L; Bokemeyer C
Br J Cancer; 2002 Sep; 87(7):729-32. PubMed ID: 12232755
[TBL] [Abstract][Full Text] [Related]
27. Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT).
Taza F; Abonour R; Zaid MA; Althouse SK; Anouti B; Akel R; Hanna NH; Adra N; Einhorn LH
Clin Genitourin Cancer; 2023 Apr; 21(2):213-220. PubMed ID: 36737276
[TBL] [Abstract][Full Text] [Related]
28. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Beyer J; Hartmann JT; Schwella N; Kingreen D; Neureither S; Metzner B; Casper J; Wandt H; Hartmann F; Schmoll HJ; Derigs G; Gerl A; Berdel WE; Kanz L; Siegert W
J Clin Oncol; 2001 Jan; 19(1):81-8. PubMed ID: 11134198
[TBL] [Abstract][Full Text] [Related]
29. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.
Rodenhuis S; de Wit R; de Mulder PH; Keizer HJ; Sleijfer DT; Lalisang RI; Bakker PJ; Mandjes I; Kooi M; de Vries EG
Ann Oncol; 1999 Dec; 10(12):1467-73. PubMed ID: 10643538
[TBL] [Abstract][Full Text] [Related]
30. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
[TBL] [Abstract][Full Text] [Related]
31. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.
Motzer RJ; Cooper K; Geller NL; Bajorin DF; Dmitrovsky E; Herr H; Morse M; Fair W; Sogani P; Russo P
Cancer; 1990 Dec; 66(12):2476-81. PubMed ID: 2174300
[TBL] [Abstract][Full Text] [Related]
32. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.
Yetisyigit T; Babacan N; Urun Y; Seber ES; Cihan S; Arpaci E; Yildirim N; Aksoy S; Budakoglu B; Zengin N; Oksuzoglu B; Yalcin BC; Alkis N
Asian Pac J Cancer Prev; 2014; 15(2):831-5. PubMed ID: 24568504
[TBL] [Abstract][Full Text] [Related]
33. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
Lotz JP; Bui B; Gomez F; Théodore C; Caty A; Fizazi K; Gravis G; Delva R; Peny J; Viens P; Duclos B; De Revel T; Curé H; Gligorov J; Guillemaut S; Ségura C; Provent S; Droz JP; Culine S; Biron P;
Ann Oncol; 2005 Mar; 16(3):411-8. PubMed ID: 15659420
[TBL] [Abstract][Full Text] [Related]
34. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
36. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors.
Lorch A; Rick O; Wündisch T; Hartmann JT; Bokemeyer C; Beyer J
J Urol; 2010 Jul; 184(1):168-73. PubMed ID: 20483152
[TBL] [Abstract][Full Text] [Related]
37. Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support.
Kollmannsberger C; Schleucher N; Rick O; Metzner B; Hartmann JT; Schöffski P; Beyer J; Casper J; Sosada M; Schmoll HJ; Böhlke I; Meisner C; Kanz L; Bokemeyer C
Eur J Cancer; 2003 Apr; 39(6):775-82. PubMed ID: 12651203
[TBL] [Abstract][Full Text] [Related]
38. Improved survival in metastatic germ-cell cancer.
Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors in patients with relapsed or primary refractory germ cell tumors.
Rejlekova K; Mego M; Sycova-Mila Z; Obertova J; Rajec J; Salek T; Mardiak J
Neoplasma; 2009; 56(3):215-23. PubMed ID: 19309224
[TBL] [Abstract][Full Text] [Related]
40. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
